These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 19284067)

  • 1. Long-term follow-up of percutaneous coronary intervention of unprotected left main lesions with drug eluting stents: predictors of clinical outcome.
    Pavei A; Oreglia JA; Martin G; Tousek P; Sharif F; Farah B; Sauguet A; Fajadet J
    EuroIntervention; 2009 Jan; 4(4):457-63. PubMed ID: 19284067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter international registry of unprotected left main coronary artery percutaneous coronary intervention with drug-eluting stents in patients with myocardial infarction.
    Lee MS; Sillano D; Latib A; Chieffo A; Zoccai GB; Bhatia R; Sheiban I; Colombo A; Tobis J
    Catheter Cardiovasc Interv; 2009 Jan; 73(1):15-21. PubMed ID: 19089930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of coronary anatomy and stenting technique on long-term outcome after drug-eluting stent implantation for unprotected left main coronary artery disease.
    Tiroch K; Mehilli J; Byrne RA; Schulz S; Massberg S; Laugwitz KL; Vorpahl M; Seyfarth M; Kastrati A;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):29-36. PubMed ID: 24332416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term clinical results following stenting of the left main stem: insights from RESEARCH (Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated at Rotterdam Cardiology Hospital) Registries.
    Onuma Y; Girasis C; Piazza N; Garcia-Garcia HM; Kukreja N; Garg S; Eindhoven J; Cheng JM; Valgimigli M; van Domburg R; Serruys PW;
    JACC Cardiovasc Interv; 2010 Jun; 3(6):584-94. PubMed ID: 20630451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials.
    Claessen BE; Smits PC; Kereiakes DJ; Parise H; Fahy M; Kedhi E; Serruys PW; Lansky AJ; Cristea E; Sudhir K; Sood P; Simonton CA; Stone GW
    JACC Cardiovasc Interv; 2011 Nov; 4(11):1209-15. PubMed ID: 22115661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early and long-term results of unprotected left main coronary artery stenosis with paclitaxel-eluting stents: the FRIEND (French multicentre RegIstry for stenting of uNprotecteD LMCA stenosis) registry.
    Carrié D; Eltchaninoff H; Lefèvre T; Silvestri M; Brunel P; Fajadet J; Moynagh A; Gilard M; Koning R; Dibie A; Darremont O; Lablanche JM; Blanchard D;
    EuroIntervention; 2011 Oct; 7(6):680-8. PubMed ID: 21986326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unprotected left main stenting with a second-generation drug-eluting stent: one-year outcomes of the LEMAX Pilot study.
    Salvatella N; Morice MC; Darremont O; Tafflet M; Garot P; Leymarie JL; Chevalier B; Lefèvre T; Louvard Y; Boudou N; Dumonteil N; Carrié D
    EuroIntervention; 2011 Oct; 7(6):689-96. PubMed ID: 21986327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term clinical outcomes after percutaneous coronary intervention for ostial/mid-shaft lesions versus distal bifurcation lesions in unprotected left main coronary artery: the DELTA Registry (drug-eluting stent for left main coronary artery disease): a multicenter registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment.
    Naganuma T; Chieffo A; Meliga E; Capodanno D; Park SJ; Onuma Y; Valgimigli M; Jegere S; Makkar RR; Palacios IF; Costopoulos C; Kim YH; Buszman PP; Chakravarty T; Sheiban I; Mehran R; Naber C; Margey R; Agnihotri A; Marra S; Capranzano P; Leon MB; Moses JW; Fajadet J; Lefevre T; Morice MC; Erglis A; Tamburino C; Alfieri O; Serruys PW; Colombo A
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1242-9. PubMed ID: 24355114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term clinical outcome of rotational atherectomy followed by drug-eluting stent implantation in complex calcified coronary lesions.
    Abdel-Wahab M; Baev R; Dieker P; Kassner G; Khattab AA; Toelg R; Sulimov D; Geist V; Richardt G
    Catheter Cardiovasc Interv; 2013 Feb; 81(2):285-91. PubMed ID: 22431433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Twelve month clinical and angiographic outcome after stenting of unprotected left main coronary artery stenosis with paclitaxel-eluting stents--results of the multicentre FRIEND registry.
    Carrié D; Eltchaninoff H; Lefèvre T; Silvestri M; Levy G; Maupas E; Brunel P; Fajadet J; Le Breton H; Gilard M; Blanchard D; Glatt B;
    EuroIntervention; 2009 Jan; 4(4):449-56. PubMed ID: 19284066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison between the NERS (New Risk Stratification) score and the SYNTAX (Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery) score in outcome prediction for unprotected left main stenting.
    Chen SL; Chen JP; Mintz G; Xu B; Kan J; Ye F; Zhang J; Sun X; Xu Y; Jiang Q; Zhang A; Stone GW
    JACC Cardiovasc Interv; 2010 Jun; 3(6):632-41. PubMed ID: 20630456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized comparison of sirolimus- versus paclitaxel-eluting stent implantation in patients with diabetes mellitus: 4-year clinical outcomes of DES-DIABETES (drug-eluting stent in patients with DIABETES mellitus) trial.
    Lee SW; Park SW; Kim YH; Yun SC; Park DW; Lee CW; Kang SJ; Rhee KS; Chae JK; Ko JK; Park JH; Lee JH; Choi SW; Jeong JO; Seong IW; Cho YH; Lee NH; Kim JH; Chun KJ; Kim HS; Park SJ
    JACC Cardiovasc Interv; 2011 Mar; 4(3):310-6. PubMed ID: 21435609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and angiographic results of angioplasty with a paclitaxel-eluting stent for unprotected left main coronary artery disease (a study of 101 consecutive patients).
    Cherradi R; Ouldzein H; Zouaoui W; Elbaz M; Puel J; Carrié D
    Arch Cardiovasc Dis; 2008 Jan; 101(1):11-7. PubMed ID: 18391867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-eluting versus bare-metal stents in unprotected left main coronary artery stenosis a meta-analysis.
    Pandya SB; Kim YH; Meyers SN; Davidson CJ; Flaherty JD; Park DW; Mediratta A; Pieper K; Reyes E; Bonow RO; Park SJ; Beohar N
    JACC Cardiovasc Interv; 2010 Jun; 3(6):602-11. PubMed ID: 20630453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of 5-year outcomes in patients with and without unprotected left main coronary artery disease after treatment with sirolimus-eluting stents: insights from the j-Cypher registry.
    Toyofuku M; Kimura T; Morimoto T; Hayashi Y; Shiode N; Nishikawa H; Nakao K; Shirota K; Kawai K; Hiasa Y; Kadota K; Nozaki Y; Isshiki T; Sone T; Mitsudo K;
    JACC Cardiovasc Interv; 2013 Jul; 6(7):654-63. PubMed ID: 23866178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of drug-eluting stent with bare metal stent for distal de novo unprotected left main coronary artery stenosis. A propensity score-matched cohort study.
    Hsueh SK; Wu CJ; Fang HY; Hsieh YK; Fang CY; Chen CJ; Chen SM; Yang CH; Yip HK; Chen MC; Fu M; Cheng CI
    Circ J; 2011; 75(2):290-8. PubMed ID: 21157111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcomes of elective drug-eluting stenting of the unprotected left main coronary artery in patients with normal left ventricular function.
    Lee MS; Yang T; Biondi-Zoccai G; Sillano D; Cerrato E; Tarantini G; Xhaxho J; Aragon J; Sheiban I
    Catheter Cardiovasc Interv; 2011 Jun; 77(7):945-51. PubMed ID: 20824773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial.
    Leon MB; Nikolsky E; Cutlip DE; Mauri L; Liberman H; Wilson H; Patterson J; Moses J; Kandzari DE;
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1043-50. PubMed ID: 20965463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Five-year long-term clinical follow-up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT FIRST trial.
    Wiemer M; Serruys PW; Miquel-Hebert K; Neumann FJ; Piek JJ; Grube E; Haase J; Thuesen L; Hamm C
    Catheter Cardiovasc Interv; 2010 Jun; 75(7):997-1003. PubMed ID: 20517959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of SYNTAX (Synergy between PCI with Taxus and Cardiac Surgery) score for prediction of outcomes after unprotected left main coronary revascularization.
    Kim YH; Park DW; Kim WJ; Lee JY; Yun SC; Kang SJ; Lee SW; Lee CW; Park SW; Park SJ
    JACC Cardiovasc Interv; 2010 Jun; 3(6):612-23. PubMed ID: 20630454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.